Salmeterol (GR33343X)
(Synonyms: 沙美特罗; GR33343X) 目录号 : GC30092
Salmeterol (Astmerole, GR-33343X, SN408D) is a long-acting beta2-adrenergic receptor agonist with Ki value of 1.5 nM for WT β2AR and shows very high selectivity for the WT β2AR(β1Ki/β2Ki ratio of approximately 1500).
Cas No.:89365-50-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Salmeterol (Astmerole, GR-33343X, SN408D) is a long-acting beta2-adrenergic receptor agonist with Ki value of 1.5 nM for WT β2AR and shows very high selectivity for the WT β2AR(β1Ki/β2Ki ratio of approximately 1500).
Salmeterol is highly lipophilic and diffuses through the lipid bilayer in muscle cell membranes to reach the β2-ARs, explaining its slow onset and long duration of action[2]. Salmeterol has been found to cause a dose-dependent increase in cAMP levels in neutrophils, an effect that is expected to reduce neutrophil-endothelial cell adhesion through inhibition of neutrophil Mac-1 cell surface expression[3].
Salmeterol decreases the production of pro-inflammatory cytokines in a model of allergen-challenged mice that expressed tumor-necrosis factor-alpha, interleukin-1 and interleukin-6[2]. Salmeterol inhibits lipopolysaccharide-induced neutrophil recruitment to the lungs by a mechanism that possibly in part is mediated by an effect on neutrophil CD11b[3].
[1] Isogaya M, et al. Mol Pharmacol. 1998, 54(4):616-22. [2] Zhenli Hu, et al. Cell Mol Immunol. 2012,(3): 267-275. [3] Maris NA, et al. Am J Physiol Lung Cell Mol Physiol. 2004, 286(6):L1122-8.
| Cas No. | 89365-50-4 | SDF | |
| 别名 | 沙美特罗; GR33343X | ||
| Canonical SMILES | OC1=CC=C(C(O)CNCCCCCCOCCCCC2=CC=CC=C2)C=C1CO | ||
| 分子式 | C25H37NO4 | 分子量 | 415.57 |
| 溶解度 | DMSO : ≥ 100 mg/mL (240.63 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4063 mL | 12.0317 mL | 24.0633 mL |
| 5 mM | 0.4813 mL | 2.4063 mL | 4.8127 mL |
| 10 mM | 0.2406 mL | 1.2032 mL | 2.4063 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet